What type of study is this?

September 10, 2025Bioanalysis

Overcoming bioanalytical challenges during the development of risdiplam for the treatment of spinal muscular atrophy

View Full Paper

Ask AI

Bookmark

Successful analysis of risdiplam and its metabolite in various samples enhances treatment for spinal muscular atrophy.
Key challenges included light sensitivity and nonspecific binding, complicating the drug measurement across species.
Bioanalytical methods were adapted to tackle issues such as carryover and the complex analysis of tissue samples.
Overcoming these bioanalytical challenges is crucial for ensuring accurate measurements in clinical settings.

Implication

Analysis identifies bioanalytical challenges measuring risdiplam in plasma and urine, suggesting improvements for drug development.

Abstract

Aims Risdiplam is a small molecule approved for the treatment of spinal muscular atrophy (SMA). The drug and its major metabolite had to be measured in plasma and tissue from several animal species and in human plasma and urine. Bioanalytical challenges including light sensitivity, instability, carryover, nonspecific binding, and complex tissue analysis, had to be overcome.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Heinig et al. (2025) studied this question.

synapsesocial.com/papers/68c18c019b7b07f3a061469d https://doi.org/10.1080/17576180.2025.2554563

View Full Paper

Ask AI

Bookmark

Implication

Analysis identifies bioanalytical challenges measuring risdiplam in plasma and urine, suggesting improvements for drug development.

Overcoming bioanalytical challenges during the development of risdiplam for the treatment of spinal muscular atrophy

Key Points

Implication

Abstract

Discussion

Cite This Study

Overcoming bioanalytical challenges during the development of risdiplam for the treatment of spinal muscular atrophy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading